A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Item
http://www.wikidata.org/entity/Q36347386
Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.Pretreated baseline neutrophil count and chemotherapy-induced neutropenia may be conveniently available as prognostic biomarkers in advanced gastric cancer.Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer.A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.Short-course neoadjuvant chemoradiotherapy and surgery are beneficial in Chinese patients: A retrospective study.Does clinical trial participation improve outcomes in patients with ovarian cancer?
P2860

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Item
http://www.wikidata.org/entity/Q36347386
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@ast
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
type
label
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@ast
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
prefLabel
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@ast
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
A multicenter, randomized tria ...... ANZGOG study on behalf of GCIG
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P932